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CASE REPORT
Patients with acromegaly develop growth hor-
mone (GH) hypersecretion with resulting eleva-
tion in circulating insulin-like growth factor-1
(IGF-1) concentrations. Hypersecretion of GH
by a pituitary GH-producing tumor is the under-
lying abnormality in more than 98% of acrome-
galy cases.1 A decreased life expectancy, with a
two- to threefold increase in mortality, is associ-
ated with the disorder.2 The two main clinical 
sequelae of untreated acromegaly are cardiovas-
cular disease and malignancy. Successful treatment
modalities can decrease these two key sequelae.
Transsphenoid surgery (TSS) is standard treat-
ment for acromegaly. However, less than 50% of
acromegalic patients with macroadenomas can
achieve satisfactory biochemical control and the
majority of acromegalic patients have macroade-
nomas.1 Therefore, many patients require addi-
tional therapy to alleviate disabling signs and
rsymptoms and control GH and IGF-1 levels afte
rinitial TSS. In addition, some patients suffe
from hypopituitarism after TSS. Medical therapy,
such as dopamine agonists and somatostatin
y analogs, has been used as adjuvant therap
ywith good effect. However, medical therap
 alone, or so-called primary medical therapy, in
r patients who have not undergone surgery o
r radiotherapy can offer the prospect of nea
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To cure acromegalic patients, transsphenoidal surgery is considered first, especially for microadenoma.
However, less than 50% of patients with macroadenoma achieve satisfactory biochemical control.
Moreover, surgery may cause hypopituitarism. Medical therapy may offer the prospect of near normali-
 zation of growth hormone (GH)/insulin-like growth factor-1 levels with substantial tumor shrinkage in
a significant number of patients. Here, we report two cases of acromegaly under treatment with somato-
statin analogs alone for more than 10 years. Case 1 was a 54-year-old man with a pituitary macro-
adenoma. He received 4 years of octreotide treatment followed by 6 years of prolonged-release (PR)
lanreotide resulting in normal GH level. Case 2 was a 60-year-old woman with a 1.3 cm pituitary tumor.
She received 8 years of octreotide treatment followed by 6 years of PR lanreotide resulting in subnormal
tGH level and gallbladder sludge. She had received bilateral total hip replacement for hip osteoarthritis a
the age of 59 years. These cases illustrate that long-term treatment with somatostatin analogs offers an
alternative choice in selected acromegalic patients, such as those with pituitary tumor who cannot be
cured by surgery, those who have unacceptable anesthetic risk and those who refuse surgery. [J Formos Med
Assoc 2006;105(8):664–669]
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l f / l l h hnorma ization o  GH IGF-1 eve s toget er wit
substantial tumor shrinkage and without effect
on normal pituitary function in a significant
number of patients.1 Here, we report two patients
treated with primary medical therapy for more
than 10 years. 
Case Reports
Case 1
This 54-year-old man had progressive enlargement
of the nose, forehead and jaw in 1993, when he
was 42 years old. Acromegaly was suspected ac-
cording to his appearance in October 1993. Skull
X-ray showed an enlarged sella. He was lost to
follow-up after hesitating to receive TSS. However,
the development of blurred vision in the left eye
led him to visit our outpatient department again
in August 1995. Elevated serum GH (25 μg/L,
normal < 5 μg/L) and prolactin (76.5 μg/L, nor-
mal < 20 μg/L) levels were noted. A grade I diffuse
goiter with elevated serum thyroxine (268 nmol/L,
normal 64–154 nmmol/L) level were also noted.
Blood pressure was 140/90 mmHg. Physical exami-
nation showed enlargement of the forehead,
nose and jaw. Multiple furuncles in the face and
trunk, increased moisture in the palms and an
enlargement of the tongue were noted. Thickened
heel pads and the enlargement of fingers and toes
were also found. Confrontation test showed no
visual field defects.
On admission, serum IGF-1 level was 1024
μg/L (normal 90–360 μg/L). Serum thyroid stimu-
lating hormone level was 3.11 mU/L (normal
0.4–5 mU/L) and free thyroxine level was 11.1
pmol/L (normal 10.3–34.8 pmol/L). He did not
have impaired glucose tolerance based on 75 g
oral glucose tolerance test (OGTT). Insulin toler-
ance test did not show any evidence of adrenal
insufficiency. Secretion of GH could not be sup-
pressed by 2.5 mg of bromocriptine. Pituitary
magnetic resonance imaging (MRI) showed a 
2.5 × 2 × 2 cm pituitary tumor at the right side of
the sella that invaded the cavernous sinus and
caused local mass effects (Figure 1). Abdominal
sonography showed gallbladder sludge. He was
treated with octreotide (Sandostatin®, Novartis,
Basel, Switzerland) 50 μg three times daily by sub-
cutaneous injection in the first 2 days and then
100 μg three times daily. There were no signi-
ficant side effects after octreotide injection. He
began to receive regular octreotide injections in
October 1995. In April 1996, his serum GH level
ywas 4.8 μg/L and MRI disclosed a smaller pituitar
tumor. His blurred vision also improved.
Valsartan 80 mg/day for hypertension (blood
pressure, 148/108 mmHg) was started in Novem-
ber 1998 and slow-release indapamide 1.5 mg/
day was added in January 1999.  Serum GH level
was 2 μg/L at that time. Somatostatin analog was
changed to prolonged-release (PR) lanreotide
(Somatulin PR 30 mg intramuscular injection
every 2 weeks) beginning in February 1999. He
did not complain of any adverse effects. His GH
rlevel was maintained at less than 2.5 μg/L unde
treatment with PR lanreotide, but blood pressure
fcould not be well controlled despite the use o
multiple antihypertensive drugs.
Case 2 
This 60-year-old woman found that she could
fnot wear her ring because of the enlargement o
fingers in 1985, when she was 42 years old.
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iF gure 1. fPituitary magnetic resonance imaging o  case 1
in October 1995 shows a 2.5 × 2 × 2 cm pituitary tumor
(arrow) at the right side of the sella invading the cavernous
sinus and causing local mass effects.
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Oligomenorrhea developed 1 year later, and she
suffered from malocclusion and intermittent
arthralgia (both knees and proximal interpha-
langeal joints of hands) 3 years later, followed by
two episodes of mild lower leg edema the fol-
lowing year. She visited a local hospital where
elevated serum GH level (36 μg/L) was found.
Head computed tomography (CT) showed a
pituitary tumor measuring 1.3 cm in diameter 
at the right side (Figure 2A). She did not have
headache, blurred vision or paresthesia.
She was admitted to our hospital in April 1990.
Blood pressure was 130/80 mmHg. Physical exam-
ination showed prognathism, frontal bossing,
grade II enlargement of the thyroid gland, oily
skin, and widely spaced teeth with malocclusion.
Her right hand volume was 300 mL and her left
hand was also 300 mL.
Analysis of serum revealed the following: basal
prolactin level 6.1 μg/L; cortisol 358 nmol/L (nor-
mal 140–690 nmol/L) at 8 am and 143 nmol/L
(normal 80–330 nmol/L) at 4 pm; estradiol
< 52.5 pmol/L; thyroid stimulating hormone 0.75
mU/L (normal 0.4–5 mU/L); triiodothyronine
1.3 nmol/L (normal 1.1–2.9 nmol/L); and thy-
roxine 102 nmol/L (normal 64–154 nmmol/L).
Basal GH was 56 μg/L, and the 75 g OGTT showed
nonsuppressible GH levels (all more than 49 μg/L)
without impaired glucose tolerance. Bromocriptine
test showed a partially suppressible response with
a trough GH level of 15 μg/L at the 6th hour.
Thyrotropin-releasing hormone test showed a nor-
mal thyrotropin response and elevated GH levels.
Skull X-ray showed a double contour of sella tur-
gcica. Knee X-ray disclosed joint space narrowin
twith osteophytes. Abdominal sonography did no
show any abnormal lesion. Subcutaneous injec-
tion of octreotide (100 μg thrice/day) was started
in April 1990, with no significant adverse effects
from the treatment.
Under treatment with octreotide, serum GH
decreased to 8 μg/L in July 1990. However, gall-
tbladder sludge without abdominal discomfor
developed. Cranial CT showed a reduction in the
size of the pituitary tumor (Figure 2B). The serum
GH level was > L75 μg/L and IGF-1 was 924 μg/m
at the time of octreotide discontinuation. She then
received octreotide at another hospital over the
following 4 years before visiting our hospital
again in 1995, at which time serum GH level was
24.5 μg/L. Pituitary MRI in March 1995 showed 
a pituitary tumor of 1.2 cm in diameter with a
predominantly left-sided suprasellar extension.
tThe optic chiasm was compressed and the righ
cavernous sinus showed tumor involvement. GH
glevel was in the range of 6–8 μg/L prior to startin
A B
iF gure 2. ( ) l d h ( ) f h h dA  Crania  compute  tomograp y CT  o  case 2 in Marc  1989 s ows a pituitary tumor, 1.3 cm in iameter,
on the right (arrow). (B) Follow-up cranial CT in October 1990 shows a smaller pituitary tumor (arrow).
PR lanreotide treatment in February 1999. The
drug was well tolerated and serum GH level 
decreased to 3–5 μg/L. Hypertension was noted
and well controlled by two antihypertensive agents. 
Bilateral hip pain developed in 2004 and the
pain worsened with weight bearing or strenuous
activities. She also complained of limitation of
range of motion of both hips. Hip X-ray showed
severe degenerative changes. Right total hip re-
placement (THR) was performed on July 27, 2004
and left THR on August 3, 2004.
Discussion
Although 85–90% of microadenomas can be
cured with TSS by an experienced surgeon, large
and/or invasive tumors are not likely to be cured
with TSS.3,4 Adjuvant medical therapy should be
considered in such patients to control GH level
and alleviate their potentially disabling signs
and symptoms. 
Dopamine agonists such as bromocriptine
and cabergoline have been used in patients with
acromegaly for several years, particularly in patients
with tumors secreting both GH and prolactin.
Cabergoline seems to be more effective than
bromocriptine. In a review of the literature in-
cluding 52 patients treated with bromocriptine,
fewer than 20% of patients had GH levels sup-
pressed below 5 μg/L.5 In a study of 64 patients
with active acromegaly treated with a weekly
dose of cabergoline between 1.0 and 1.75 mg for
3–40 months, a decrease in IGF-1 below 300
μg/L was observed in 39% of patients, and a
decrease in random GH below 2 μg/L in 46% of
patients. Responses were more marked in
patients with tumors secreting both GH and
prolactin.6 Although dopamine agonists can sup-
press GH secretion, GH levels are rarely reduced
to acceptable values.
Since their introduction into clinical practice,
somatostatin analogs have been the medical ther-
apy of choice for the treatment of acromegaly.
Octreotide is a long-acting synthetic somatostatin
analog. Over a 6-month period, GH decreased to
y2.5 μg/L in 22–45% of patients with acromegal
treated with octreotide.1,7 fFor a given dose o  
octreotide, continuous infusions have been shown
to be more effective than subcutaneous regimens.
This observation, along with the inconvenience
of three times daily administration, has led to
ythe development of a depot preparation. In a stud
of long-acting repeatable octreotide (Sandostatin
LAR, Novartis), suppression of mean GH concen-
tration below 5 μg/L was recorded in 94% of pa-
tients and below 2 μg/L tin 56%. At the endpoin
of the study, IGF-1 was within the normal range
in 66% of patients.8 PR lanreotide (Somatulin PR,
Beaufour-Ipsen, Paris, France) is an alternative
long-acting somatostatin analog. In a 12-month
multicenter study from France, 41% of patients
had GH concentrations below 2.5 μg/L and 41%
had IGF-1 values in the normal range at the end
of the study period.9
tIn several studies of preoperative treatmen
with somatostatin analogs, lowering on GH and
IGF-1 levels and variable effects on adenoma
growth were observed.10–12 These findings, as
fwell as reported observations of the effects o
octreotide in previously untreated patients with
acromegaly,13 have led to the development of the
concept of primary medical therapy.14–17
Treatment with octreotide LAR led to a
decrease in tumor volume in 12 on 15 (80%)
previously untreated patients, and no patient had
tumor re-expansion during treatment.15 rIn anothe
study, 73% of 27 patients showed more than
30% tumor volume shrinkage.17 Freda reviewed
ystudies assessing tumor shrinkage with primar
tsomatostatin analog therapy and found tha
tumor shrinkage was reported in 48% of pa-
tients, with most tumor shrinkage between 20%
and 50%.18 Our patients had smaller or stabi-
lized tumor sizes after the usage of somatostatin
analogs.
To decrease mortality caused by acromegaly,
a GH level < f2 or 2.5 μg/L on random or mean o
hourly sampling or < 1.0 μg/L after oral glucose
suppression should be obtained by therapy.1,18
yStudies of hormone level changes under primar
somatostatin analog therapy reported that GH
Somatostatin analogs and acromegaly
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control was achieved in approximately 75% of pa-
tients, and 53% achieved normal IGF-1 levels.15,17
Freda’s review of overall data from all combined
analogs revealed that IGF-1 was normalized in
60% of patients, and GH was suppressed in 50%
of patients.18 These figures are similar to the
results of studies where the analogs were used as
adjunctive therapy.14,15 Colao et al found that 
GH and IGF-1 suppression during Sandostatin
LAR treatment was similar in de novo and oper-
ated patients as shown by nadir GH (2.3 μg/L vs.
2.2 μg/L) and IGF-1 (323.1 μg/L vs. 275.5 μg/L),
percent suppression of GH (92.7% vs. 85.6%) and
IGF-1 (57.4% vs. 61.5%), and prevalence of GH
(73.3% vs. 76.2%) and IGF-1 (53.3% vs. 71.4%)
control.15
TSS performed by an experienced operator 
in an expert unit achieves satisfactory biochemi-
cal control (mean GH < 2.5 μg/L, GH nadir after
OGTT < 1 μg/L, normal IFG-1) in 80–90% of 
patients with microadenomas and less than
50% with macroadenomas.1 TSS has the greatest
cost-benefit among treatments for possibly cur-
able patients with acromegaly. For tumors with
cosecretion of GH and prolactin, the oral route
of dopamine agonist administration and its
low cost are two main advantages compared to
somatostatin analogs.19 If GH cannot be sup-
pressed to an acceptable level with somatostatin
analogs, the addition of dopamine agonists 
is of benefit in the biochemical control of
acromegaly. Furthermore, the beneficial effects
of dopamine agonists occur even when pretreat-
ment prolactin levels are within the normal
range.20 In our patients, good control was achieved
with somatostatin analogs. Except for the devel-
opment of gallbladder sludge, they tolerated 
somatostatin analogs well.
The presence of visual or neurologic compro-
mise is almost an indication for TSS because
analog therapy may not provide enough shrinkage
to relieve pressure on the optic chiasm.21 Micro-
adenomas have a high cure rate from TSS of up to
85–90%, which is far better than the success rate of
somatostatin analog therapy. Well-circumscribed
macroadenomas also have a cure rate of 65–70%
in the hands of an experienced surgeon.4 Patients
with such conditions may be referred for opera-
tion. Other patients whose conditions are less
amenable to surgery could select primary medical
therapy as the alternative. These patients may have
good tolerance and control under long-term treat-
ment with somatostatin analogs.
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